Moderna's Omicron-Adapted Booster Maintains Response Through Three Months

Moderna Inc MRNA COVID-19 vaccine booster targeting the BA.1 subvariant of Omicron generated a strong immune response against that variant.
Ninety days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 (updated vaccine) elicited a superior neutralizing antibody response against Omicron BA.1 when compared to a 50 µg booster dose of mRNA-1273 in all participants regardless of prior infection.
Related: Moderna Inks Deal For Updated COVID Shots For Low-Income Countries.
"Clinical trial data now indicates that the superior immune response produced by our bivalent booster has durability for at least three months," Moderna Chief Executive Officer Stephane Bancel said in a statement.
Moderna expects data from human trials of its BA.4/BA.5 targeted vaccine later this year.
Last week, FDA granted emergency use authorization for Moderna's BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children and adolescents 6 - 17 years.
On Tuesday, a Morgan Stanley analyst highlighted concerns regarding Moderna's vaccine revenue guidance, mentioning, "Investors are concerned about management's ability to bracket consensus expectations of ~$10 billion in COVID vaccine revenues."
Price Action: MRNA shares are down 6.64% at $125.19 on the last check Wednesday.
Photo via Wikimedia Commons